Recent developments in the 340B program reveal escalating tensions between hospitals and pharmaceutical companies, along with ongoing legal challenges to federal policies. Five hospitals in Massachusetts have filed a lawsuit against Eli Lilly, alleging unlawful cutoffs of 340B discounts due to demands for patient claims data. In a related action, Missouri Attorney General Catherine Hanaway issued a cease-and-desist letter to Eli Lilly, calling for an end to similar data requirements. Meanwhile, hospitals have initiated a lawsuit against the Department of Health and Human Services (HHS) to block a controversial 340B rebate pilot, citing concerns over financial viability. These legal actions coincide with significant apprehension among health systems regarding proposed payment cuts by the Centers for Medicare & Medicaid Services (CMS), which could result in losses of up to $109 million annually. As the 340B rebate pilot approaches its launch, uncertainty and potential repercussions for covered entities remain.
Five Massachusetts hospitals filed a lawsuit against Eli Lilly, alleging unlawful 340B discount cutoffs for not providing patient claims data.
Missouri AG Catherine Hanaway issued a cease-and-desist letter to Eli Lilly, demanding an end to 340B claims data requirements.
Hospitals filed a lawsuit against HHS to block the 340B rebate pilot, citing financial viability concerns.
Health systems estimate significant financial losses from CMS’s proposed 340B payment cuts, totaling up to $109 million annually.
HRSA’s 340B rebate pilot is set to start in two months, with ongoing legal and legislative challenges.
Recent changes to the 340B program by the Trump administration face legal challenges from hospital groups.
- Hospitals face financial risks due to potential loss of 340B discounts if data demands persist.
- Drugmakers may encounter legal repercussions from states challenging their 340B policies.
- The 340B rebate pilot could strain hospital cash flows if implemented without changes.
- CMS’s proposed 340B payment cuts could lead to significant revenue losses for health systems.
- Hospitals can advocate for legislative changes to protect 340B discounts.
- States can use legal actions to enforce compliance with 340B program requirements.
- Congress has the opportunity to reform the 340B program through proposed legislation.
- Healthcare systems can explore alternative financial strategies to mitigate 340B payment cuts.
- Hospitals should prepare for potential changes in 340B discount structures.
- State AGs can continue to monitor and challenge drugmakers’ 340B practices.
- Lawmakers should consider the implications of delaying the 340B rebate pilot.
- Healthcare providers must assess the financial impact of CMS’s proposed 340B cuts.
- Five Massachusetts hospitals filed a lawsuit against Eli Lilly on Oct. 27.
- The lawsuit alleges unlawful cutoff of 340B discounts for not providing claims data.
- Hospitals claim Lilly violated Massachusetts consumer protection law and was unjustly enriched.
- Missouri AG issued a cease-and-desist letter to Eli Lilly on Oct. 26.
- The letter demands an end to 340B claims data requirements for discounts.
- AG claims Lilly made false statements and violated state law.
- Health systems estimate financial losses from CMS’s proposed 340B payment cuts.
- Estimates range from $7 million to $109 million annually.
- CMS’s 2027 rule would reduce payments for 340B drugs by $4.55 billion in the first year.
- HHS report suggests 340B program has expanded beyond its original intent.
- The report raises concerns about hospital profit prioritization over patient care.
- It addresses issues with spread pricing and program costs.
- HRSA’s 340B rebate pilot is set to start in two months.
- Hospitals will pay full price upfront for 21 drugs and wait for rebates.
- Legal and legislative challenges could affect the pilot’s launch.
- Missouri AG issued a cease-and-desist letter to Eli Lilly on Oct. 26.
- The letter orders Lilly to stop requiring 340B hospitals to submit claims data.
- Failure to comply may lead to enforcement action under state law.
| Court | Matter | Date |
|---|---|---|
| D. Mass. | Massachusetts hospitals v. Eli Lilly (filed) [source] | October 27, 2026 |
| D. Me. | American Hospital Association v. Kennedy (motion to intervene) [source] | October 16, 2026 |
| D. Me. | Hospitals v. HHS (filed) [source] | October 12, 2026 |
| Manufacturer | Action | Date |
|---|---|---|
| Eli Lilly | Cease-and-desist order from Missouri AG on 340B claims data requirement. [source] | October 27, 2026 |
I searched for recent stakeholder and social commentary on the U.S. 340B Drug Pricing Program from the past 90 days, focusing on reactions, statements, op-eds, and advocacy positions from hospital and health-center groups, provider and patient advocates, drug manufacturers, PBMs, and policy commentators, including LinkedIn posts, Reddit discussions, and Substack/newsletter opinions.
- Main theme: Hospital groups oppose the 340B rebate pilot program set to begin in 2027.
- Stakeholder sentiment: Hospital groups and community hospitals are opposing the pilot program, expressing concerns over its impact on the 340B program.
- Potential implications: Potential delay or modification of the 340B rebate pilot program.
- Credibility: All the News is a news aggregation platform; cross-reference with primary sources.
- Main theme: Experts discuss the 340B program’s role and the need for increased transparency.
- Stakeholder sentiment: Shawn Gremminger and Tom Kraus analyze the program’s role and the need for increased transparency.
- Potential implications: Potential policy shifts towards greater transparency in the 340B program.
- Credibility: Drug Topics is a reputable publication; verify information with primary sources.
- Main theme: ASHP members provide Congress with examples of the 340B program’s value.
- Stakeholder sentiment: ASHP members share real-world examples to demonstrate the program’s value to Congress.
- Potential implications: Potential influence on legislative support for the 340B program.
- Credibility: ASHP is a professional association; consider the context of the advocacy.
- Monitor the outcome of Massachusetts hospitals’ lawsuit against Eli Lilly. [source]
- Watch for legislative progress on the 340B Rebate Model Delay Act. [source]
- Track the impact of Missouri AG’s cease-and-desist order on Eli Lilly’s 340B practices. [source]
- Observe developments in the lawsuit against HRSA’s 340B rebate pilot. [source]
This briefing is provided for informational purposes only and does not constitute legal, regulatory, financial, or compliance advice. Automated summarization may contain errors or omissions, and source materials may change after publication. Recipients should independently verify all information against the cited primary sources before relying on it.
© 2026 MedMatrix Rx. All rights reserved.